Treatment for osteoporosis in people with ß-thalassaemia

Bhardwaj, Amit; Swe, Kye Mon Min; Sinha, Nirmal K.; Osunkwo, Ifeyinwa

doi:10.1002/14651858.cd010429.pub2

Cited by 28 publications

(23 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is no universal consensus regarding when and how to carry out such an assessment for all the pathologies involved. Following the existing guidelines for each pathology is therefore recommended [8][9][10][11][12][13][14][15][16][17][18][19][20][21][22].…”

Section: Resultsmentioning

confidence: 99%

Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

et al. 2020

View full text Add to dashboard Cite

Background: Osteoporosis incidence in children is increasing due to the increased survival rate of patients suffering from chronic diseases and the increased use of drugs that can damage bones. Recent changes made to the definition of childhood osteoporosis, along with the lack of guidelines or national consensuses regarding its diagnosis and treatment, have resulted in a wide variability in the approaches used to treat this disease. For these reasons, the Osteogenesis Imperfecta and Childhood Osteoporosis Working Group of the Spanish Society of Pediatric Rheumatology has sounded the need for developing guidelines to standardize clinical practice with regard to this pathology. Methods: An expert panel comprised of 6 pediatricians and 5 rheumatologists carried out a qualitative literature review and provided recommendations based on evidence, when that was available, or on their own experience. The level of evidence was determined for each section using the Oxford Centre for Evidence-based Medicine (CEBM) system. A Delphi survey was conducted for those recommendations with an evidence level of IV or V. This survey was sent to all members of the SERPE. All recommendations that had a level of agreement higher or equal to 70% were included. Results: Fifty-one recommendations, categorized into eight sections, were obtained. Twenty-four of them presented an evidence level 4 or 5, and therefore a Delphi survey was conducted. This was submitted electronically and received a response rate of 40%. All recommendations submitted to the Delphi round obtained a level of agreement of 70% or higher and were therefore accepted. Conclusion: In summary, we present herein guidelines for the prevention, diagnosis and treatment of secondary childhood osteoporosis based on the available evidence and expert clinical experience. We believe it can serve as a useful tool that will contribute to the standardization of clinical practice for this pathology. Prophylactic measures, early diagnosis and a proper therapeutic approach are essential to improving bone health, not only in children and adolescents, but also in the adults they will become in the future.

show abstract

Section: Resultsmentioning

confidence: 99%

Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Zoledronic acid was administered every 3 months in patients with osteoporosis. This 4-mg dose was administered every 3 months according to current osteoporosis management guidelines ( 15 ). Patients who were unable to continue this course of treatment (often due to adverse events) were given an annual IV dose in its place.…”

Section: Methodsmentioning

confidence: 99%

“…Zoledronic acid has been tested with different dosing regimens (4 mg IV every 3 months or 4 mg IV every 6 months) for osteoporosis management in thalassemia patients ( 11 ). Zoledronic acid 4 mg IV every 3 months is one of the most promising protocols ( 8 - 9 , 12 ) but evidence is lacking with respect to other potential doses (such as IV zoledronic acid administered annually) for the treatment of low BMD associated with thalassemia ( 13 - 15 ). Studies have shown that 5-mg IV zoledronic acid administered once annually can lead to increased BMD and reduced bone resorption and formation in women with postmenopausal osteoporosis ( 16 ).…”

Section: Introductionmentioning

confidence: 99%

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in beta-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy

Darvishi‐Khezri¹,

Kosaryan²,

Akbarzadeh³

et al. 2018

Med Arch

View full text Add to dashboard Cite

Introduction:The benefit of annual administration of zoledronic acid in the management of thalassemia-associated osteoporosis is unknown.Aim:The aims of this study were to evaluate the efficacy of treatment with two different dosing regimens of IV zoledronic acid (annually versus every 3 months) for increasing low bone mineral density (BMD) in patients with osteoporosis associated with β-thalassemia as annually and 3-monthly on bone density in patients.Materials and Methods:This retrospective, single-center study analyzed patients’ clinical records and bone density measurements. Those enrolled in the study were 14 to 53 years of age, had documented β-thalassemia, and were treated with IV zoledronic acid on either an annual or every 3 months dosing regimen. Dual-energy X-ray absorptiometry was used to obtain the z-score for BMD in the lumbar spine and femoral neck.Results:Thirty-four patients were enrolled in the study; 15 (44.1%) had been treated annually, and 19 (55.9%) had been treated every month. In patients receiving treatment with the once-yearly dose of zoledronic acid, significant increases were observed in the lumbar spine BMD z-score, from -2.45 ± 0.69 to -1.97 ± 0.82 (P=0.02). When comparing BMD across the two treatment regimens, the mean lumbar spine BMD was 0.82 greater (95% CI 0.31, 1.33, P=0.003) and the mean femoral neck BMD 0.37 greater (95% CI -0.15, 0.87, P=0.1) in the group receiving annual zoledronic acid treatment.Conclusions:In patients with thalassemia-associated osteopenia, annual treatment with zoledronic acid increases lumbar spine bone density while being more effective, less expensive, and associated with fewer adverse events than dosing every 3 months.

show abstract

“…The interaction of energetic particles and radiation from the Sun with the atmospheres of planets, their satellites, and comets produces X-radiation through a number of physical processes: scattering, fluorescence, charge exchange, or the stimulation of auroral activity. Chandra has observedin many cases discovered -X-rays from Venus [26]; the Earth [27] and its moon [28]; Mars [29]; Jupiter [30,31], its aurorae [32], some of its moons [31,32] and the Io plasma torus [31]; Saturn [33,34] and its rings [35]; and numerous comets [36,37]. For overviews of these observations, see e.g.…”

Section: Solar System Objectsmentioning

confidence: 99%

“…Prior to Chandra, the origin of cometary X-rays was debated. Now, observational and theoretical work has demonstrated that charge-exchange collisions of highly charged solar wind ions with cometary neutral species are the best explanation for the observed X-ray emission [32]. Chandra has also been used to discover X-ray signatures of charge exchange in the exospheres of Venus and Mars, enabling measurement of the planetary outgassing rates.…”

Section: Solar System Objectsmentioning

confidence: 99%

Highlights and discoveries from theChandraX-ray Observatory

et al. 2014

View full text Add to dashboard Cite

Within 40 years of the detection of the first extra-solar x-ray source in 1962, NASA's Chandra X-ray Observatory has achieved an increase in sensitivity of 10 orders of magnitude, comparable to the gain in going from naked-eye observations to the most powerful optical telescopes over the past 400 years. Chandra is unique in its capabilities for producing sub-arcsecond x-ray images with 100-200 eV energy resolution for energies in the range 0.08 < E < 10 keV, locating x-ray sources to high precision, detecting extremely faint sources, and obtaining high-resolution spectra of selected cosmic phenomena. The extended Chandra mission provides a long observing baseline with stable and well-calibrated instruments, enabling temporal studies over timescales from milliseconds to years. In this report we present a selection of highlights that illustrate how observations using Chandra, sometimes alone, but often in conjunction with other telescopes, have deepened, and in some instances revolutionized, our understanding of topics as diverse as protoplanetary nebulae; massive stars; supernova explosions; pulsar wind nebulae; the superfluid interior of neutron stars; accretion flows around black holes; the growth of supermassive black holes and their role in the regulation of star formation and growth of galaxies; impacts of collisions, mergers, and feedback on growth and evolution of groups and clusters of galaxies; and properties of dark matter and dark energy.

show abstract

Treatment for osteoporosis in people with ß-thalassaemia

Abstract: Treatment for osteoporosis in people with ß-thalassaemia (Review)

Cited by 28 publications

References 42 publications

Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children

Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in beta-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy

Highlights and discoveries from theChandraX-ray Observatory

Contact Info

Product

Resources

About